

Clinical Trial Protocol

Iranian Registry of Clinical Trials

27 Jul 2026

Comparative study of the effect of immunotherapy with hydroxychloroquine and vitamin D3 compared to vitamin D3 alone in patients with recurrent miscarriage

Protocol summary

Study aim

Comparison of the results of using a combination of hydroxychloroquine and vitamin D3 compared to vitamin D alone on live birth in women with a history of recurrent miscarriage

Design

The clinical trial will be conducted in a controlled, double-blind, randomized, phase 2 and 3, parallel-group design on 80 eligible subjects. The sealed envelope method will be used for randomization.

Settings and conduct

Eligible women aged 18–40 years at Imam Reza and Ghaem hospitals in Mashhad will be divided into two groups after randomization: Intervention group: 200 mg of hydroxychloroquine every 12 hours + 1000 units of vitamin D3 daily from 6 to 20 weeks of pregnancy. Control group: Routinely receive 1000 units of vitamin D3 daily. Examinations will be performed by ultrasound. The study is double-blind, and the assessors and analysts are unaware of the groups.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Women aged 18 to 40 years, trying to conceive, with at least 2 consecutive first-trimester miscarriages of unknown origin, a normal parental karyotype, no uterine abnormalities, serum vitamin D level 30 to 100, and consent to participate in the study. Exclusion criteria: Pregnancy at entry or normal pregnancy after the last miscarriage, antiphospholipid syndrome (persistent positive APL + Myakis criteria), contraindications for hydroxychloroquine or vitamin D, other chronic diseases, history of epilepsy or psychotic disorders, recent use of hydroxychloroquine or vitamin D in the past two months.

Intervention groups

Control group: A group of 40 people is eligible for inclusion and receives 1000 units of oral vitamin D3 daily. Intervention group: A group of 40 people is eligible

for inclusion and receives 200 mg of oral hydroxychloroquine twice daily, every 12 hours, along with 1,000 units of oral vitamin D3 daily.

Main outcome variables

Frequency of ongoing pregnancy

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20250507065634N3**

Registration date: **2025-08-24, 1404/06/02**

Registration timing: **prospective**

Last update: **2025-08-24, 1404/06/02**

Update count: **0**

Registration date

2025-08-24, 1404/06/02

Registrant information

Name

mahnaz shafaei fallah

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 915 930 0704

Email address

articlelab.com@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2025-09-17, 1404/06/26

Expected recruitment end date

2025-11-21, 1404/08/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparative study of the effect of immunotherapy with hydroxychloroquine and vitamin D3 compared to vitamin D3 alone in patients with recurrent miscarriage

Public title

Comparing the effect of immunotherapy with hydroxychloroquine and vitamin D3

Purpose

Prevention

Inclusion/Exclusion criteria**Inclusion criteria:**

Women between the ages of 18 and 40 Women who are trying to conceive Women with a history of at least two consecutive first-trimester miscarriages of unknown origin, with normal parental karyotype, absence of uterine abnormalities associated with recurrent miscarriage Normal serum vitamin D levels (above 30) and less than 100 Consent to participate in the study

Exclusion criteria:

Pregnancy at the time of study entry Normal pregnancy since last miscarriage Antiphospholipid syndrome with persistently positive APL antibodies and the presence of clinical conditions of APS based on Myakis criteria Known contraindications for the use of hydroxychloroquine or vitamin D Other chronic diseases History of epilepsy or psychotic disorders History of recent use of hydroxychloroquine or vitamin D in the past two months

Age

From **18 years** old to **40 years** old

Gender

Female

Phase

2-3

Groups that have been masked

- Care provider
- Outcome assessor
- Data analyser

Sample size

Target sample size: **80**

Randomization (investigator's opinion)

Randomized

Randomization description

Experimental and control groups: After selecting the sample, in the next step, people are divided into experimental and control groups using a random method. How to perform randomization: First step: After selecting the voluntary sample, all selected people are placed on a list (numbers from one to 80 are assigned to people). Second step: From these individuals, a random method is used to divide them into two experimental groups and a control group, using sealed and opaque (numbered) envelopes. Each person randomly selects an envelope and is divided into the corresponding group.

Blinding (investigator's opinion)

Double blinded

Blinding description

The study was double-blind. Participants were assigned to groups using sealed, opaque envelopes containing an allocation code (A and B). These envelopes were opened as individuals arrived, and each participant's unique code was recorded. The main study coordinator was responsible for maintaining the allocation list and did not interfere with the assessment or care process. Participants and caregivers were unaware of their assigned group. Information about the type of possible intervention, medications, and possible drug side effects was explained to participants, and consent was obtained from participants. The outcome assessors also only saw the participant identification code and did not have access to information about the groups. The intervention and control packages were identical in appearance and packaging to prevent their identification.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Research Ethics Committees of Imam Reza Hospital Educational, Research and Treatment Center- Mashhad

Street address

Basement Floor (-1), Educational Complex Building, Imam Reza Hospital, Mashhad, Khorasan Razavi, Iran

City

Mashhad

Province

Razavi Khorasan

Postal code

9137913316

Approval date

2025-08-04, 1404/05/13

Ethics committee reference number

IR.MUMS.IRH.REC.1404.111

Health conditions studied**1****Description of health condition studied**

Recurrent Pregnancy Loss

ICD-10 code

O26.2

ICD-10 code description

Pregnancy care for patient with recurrent pregnancy loss

2

Description of health condition studied

Spontaneous abortion

ICD-10 code

O03

ICD-10 code description

Spontaneous abortion

Primary outcomes

1

Description

Frequency of ongoing pregnancy

Timepoint

Week 20 onwards

Method of measurement

Ultrasound

Secondary outcomes

1

Description

Repeated miscarriage

Timepoint

Before week 20

Method of measurement

Fetal loss before 20 weeks with Ultrasound

2

Description

Gestational age at the time of miscarriage

Timepoint

Number of weeks of pregnancy

Method of measurement

Ultrasound

3

Description

Fetal abnormalities

Timepoint

Weeks 6-8, 11-13, 18-22 of pregnancy

Method of measurement

Ultrasound

Intervention groups

1

Description

Control group: They will receive oral vitamin D3 1000 units daily after a positive pregnancy test and confirmation of intrauterine pregnancy with serial pregnancy tests or vaginal ultrasound until the 20th week of pregnancy. Ultrasound will be performed at 6-8, 11-13, and 18-22 weeks of pregnancy.

Category

Placebo

2

Description

Intervention group: Receive oral hydroxychloroquine 200 mg twice daily every 12 hours along with oral vitamin D3 1000 units daily after a positive pregnancy test and confirmation of intrauterine pregnancy with serial titration of pregnancy test or vaginal ultrasound until the 20th week of pregnancy. Ultrasound will be performed at 6-8 weeks, 11-13 weeks, and 18-22 weeks of pregnancy.

Category

Diagnosis

Recruitment centers

1

Recruitment center

Name of recruitment center

Imam Reza Hospital

Full name of responsible person

Salman Soltani

Street address

Imam Reza Educational, Research and Treatment Center, Imam Reza Hospital Square, Avicenna (Ibn Sina) Street, Mashhad, Khorasan Razavi, Iran

City

Mashhad

Province

Razavi Khorasan

Postal code

911379113316

Phone

+98 51 3854 3031

Email

IRH.CRU@mums.ac.ir

2

Recruitment center

Name of recruitment center

Ghaem Hospital

Full name of responsible person

Mostafa Dastan

Street address

Qaem Hospital, Ahmadabad Street, Mashhad, Khorasan Razavi, Iran

City

Mashhad

Province

Razavi Khorasan

Postal code

99199-91766

Phone

+98 51 3840 0000

Email

ghh.pr@mums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Mohsen Tafaghodi

Street address

Research Affairs Management, Central Building,
Mashhad University of Medical Sciences, Daneshgah
Street, Mashhad, Khorasan Razavi, Iran

City

Mshhad

Province

Razavi Khorasan

Postal code

9138813944

Phone

+98 51 3841 1538

Email

RAMResearch@mums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Mashhad University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Shaghayegh Jahantigh

Position

Resident

Latest degree

Medical doctor

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Unit 405, Soroush Building, Elaheieh 16, Mashhad,
Khorasan Razavi, Iran

City

Mashhad

Province

Razavi Khorasan

Postal code

9116333709

Phone

+98 936 600 3045

Email

jahantigh.sh71@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Malihe Afiat

Position

Associate Professor

Latest degree

Subspecialist

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Between Khaqani 5 and 7, Khaqani Boulevard,
Mashhad, Khorasan Razavi, Iran

City

Mashhad

Province

Razavi Khorasan

Postal code

9177740015

Phone

+98 915 505 6897

Email

Afiatm@mums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Shaghayegh Jahantigh

Position

Resident

Latest degree

Medical doctor

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Unit 405, Soroush Building, Elaheieh 16, Mashhad,
Khorasan Razavi, Iran

City

Mashhad

Province

Razavi Khorasan

Postal code

9116333709

Phone

+98 936 600 3045

Email

jahantigh.sh71@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Demographic data and the main outcome results of the research can be shared after de-identification and preserving the privacy of individuals.

When the data will become available and for how long

Data can be made available 4 months after the results are published and after personally identifiable information is removed.

To whom data/document is available

The study data and documentation will be available to researchers and scholars working at reputable academic and scientific institutions.

Under which criteria data/document could be used

Research data and documentation may be used for scientific and research purposes. Users must undertake to keep non-identifiable data confidential.

From where data/document is obtainable

If you need data, please contact
jahantigh.sh71@gmail.com

What processes are involved for a request to access data/document

After receiving and reviewing the request from the researcher, the request will be responded to as soon as possible.

Comments